載入中
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
一般交易時段
US$3.5331
−US$0.1869 · -5.02%
盤中時間採用ET。市場資料可能有所延遲。
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
日內區間
目前US$3.5331
52週區間
目前US$3.5331
盤中時間採用ET。市場資料可能有所延遲。
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
日內區間
目前US$3.5331
52週區間
目前US$3.5331
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.5億 USD | 1.48億 USD | 5719.3萬 USD | 1.5億 USD | 7564.3萬 USD |
| 銷貨成本 | 4318.1萬 USD | 1229.9萬 USD | 822.2萬 USD | 738.4萬 USD | 265.1萬 USD |
| 毛利 | 1.06億 USD | 1.36億 USD | 4897.1萬 USD | 1.43億 USD | 7299.2萬 USD |
| 研究與開發 | 1.4億 USD | 1.77億 USD | 1.67億 USD | 2.07億 USD | 2.15億 USD |
| 銷售、一般及管理費用 | 3916萬 USD | 7104.7萬 USD | 5218.8萬 USD | 5894.9萬 USD | 6301.4萬 USD |
| 營業費用 | 1.79億 USD | 2.47億 USD | 2.17億 USD | 2.64億 USD | 2.76億 USD |
| 利息收入 | 340萬 USD | 942.1萬 USD | 968.6萬 USD | 170萬 USD | 68萬 USD |
| 利息支出 | 850.8萬 USD | 111.5萬 USD | 143萬 USD | — | — |
| 折舊和攤銷 | 717.2萬 USD | 754萬 USD | 964.5萬 USD | 1186.5萬 USD | 1125.8萬 USD |
| 營業利益 | −7284.1萬 USD | −1.11億 USD | −1.68億 USD | −1.21億 USD | −2.03億 USD |
| 淨利 | −7462萬 USD | −6696.6萬 USD | −905.8萬 USD | −1.2億 USD | −2.02億 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.00
上漲空間 69.82%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI768.28萬0.00%2.3兆 USD0.03%US$381.3-0.07%
iShares Russell 2000 ETFIWM577.85萬0.01%787.4億 USD0.19%US$277.02-0.32%
Vanguard Extended Market ETFVXF265.95萬0.00%954億 USD0.05%US$232.82-0.30%
iShares Russell 2000 Growth ETFIWO190.12萬0.01%139.17億 USD0.24%US$351.67-0.58%
Vanguard Russell 2000 ETFVTWO144.36萬0.01%180億 USD0.06%US$111.88-0.35%
Fidelity Enhanced Small Cap ETFFESM118.3萬0.02%64.1億 USD0.28%US$45.155-0.19%
iShares Micro-Cap ETFIWC73.09萬0.06%13.17億 USD0.60%US$180.05-0.89%
iShares Russell 2000 Value ETFIWN33.47萬—137.49億 USD0.24%US$210.97-0.06%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCiShares Russell 2000 Value ETFIWNAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
